{"product_id":"antiviral-drugs-isbn-9780470455630","title":"Antiviral Drugs","description":"This book focuses on new small molecule approaches to combat viral infections. The chapters describe the discovery and development from bench through the clinic of relatively recently-approved antiviral drugs and compounds in advanced clinical development. Organized by a virus (such as HIV, HCV, RSV, influenza, HBV and CMV) and written by top academic and industrial authorities in the field, the book provides a unique opportunity to study, understand and apply discovery and development principles and learning without the need for an individual to research, analyze and synthesize all immense sourcing references.  Topics showcase challenges and solutions of issues encountered, offering tremendous experience accumulated over many years of research that will be particularly useful to basic and bench scientists as well as clinicians as they continue discovering and developing new drugs and therapies. \u003cp\u003eContributors ix\u003c\/p\u003e \u003cp\u003ePreface xiii\u003c\/p\u003e \u003cp\u003e\u003cb\u003ePart I Human Immunodeficiency Virus \u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003eSection I HIV Protease Inhibitors\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e1 Discovery and Development of Atazanavir 3\u003cbr\u003e \u003ci\u003eAwny Farajallah, R. Todd Bunch, and Nicholas A. Meanwell\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e2 Discovery and Development of PL-100, A Novel HIV-1 Protease Inhibitor 19\u003cbr\u003e \u003ci\u003eJinzi J. Wu and Joseph Musto\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e3 Darunavir (Prezista, TMC114): From Bench to Clinic, Improving Treatment Options for HIV-InfectedPatients 31\u003cbr\u003e \u003ci\u003eMarie-Pierre de Béthune, Vanitha Sekar, Sabrina Spinosa-Guzman, Marc Vanstockem, Sandra De Meyer, Piet Wigerinck, and Eric Lefebvre\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e4 Discovery and Development of Tipranavir 47\u003cbr\u003e \u003ci\u003eKaren R. Romines\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003eSection II HIV Non-nucleoside Reverse Transcriptase Inhibitors\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e5 TMC278 (Rilpivirine): A Next-Generation NNRTI in Phase III Clinical Development for Treatment-Naive Patients 59\u003cbr\u003e \u003ci\u003eJérôme Guillemont, Katia Boven, Herta Crauwels, and Marie-Pierre de Béthune\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e6 Etravirine: From TMC125 to Intelence: A Treatment Paradigm Shift for HIV-Infected Patients 71\u003cbr\u003e \u003ci\u003eKoen Andries, Ann Debunne, Thomas N. Kakuda, Michael Kukla, Ruud Leemans, Johan Vingerhoets, Brian Woodfall, and Marie-Pierre de Béthune\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003eSection III HIV Nucleoside Reverse Transcriptase Inhibitors\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e7 Discovery and Development of Tenofovir Disoproxil Fumarate 85\u003cbr\u003e \u003ci\u003eErik De Clercq\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e8 Discovery and Development of Apricitabine 103\u003cbr\u003e \u003ci\u003eSusan Cox, John Deadman, Justine Southby, and Jonathan Coates\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003eSection IV HIV Entry Inhibitors\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e9 Discovery and Development of Maraviroc and PF-232798: CCR 5 Antagonists for the Treatment of HIV-1 Infection 117\u003cbr\u003e \u003ci\u003ePatrick Dorr and Paul Stupple\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e10 Discovery of the CCR5 Antagonist Vicriviroc (Sch 417690\/Sch-D) for the Treatment of HIV-1Infection 137\u003ci\u003e\u003cbr\u003e Jayaram R. Tagat, Julie M. Strizki, and Lisa M. Dunkle\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e11 Discovery and Development of HIV-1 Entry Inhibitors That Target gp 120 149\u003cbr\u003e \u003ci\u003eJohn F. Kadow, John Bender, Alicia Regueiro-Ren, Yasutsugu Ueda, Tao Wang, Kap-Sun Yeung, and Nicholas A. Meanwell\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003eSection V HIV Integrase Inhibitors\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e12 Discovery of MK-0536: A Potential Second-Generation HIV-1 Integrase Strand Transfer Inhibitorwith a High Genetic Barrier to Mutation 163\u003cbr\u003e \u003ci\u003eMelissa S. Egbertson, John S. Wai, Mark Cameron, and R. Scott Hoerrner\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e13 Discovery and Development of HIV Integrase Inhibitor Raltegravir 181\u003cbr\u003e \u003ci\u003eVincenzo Summa and Paola Pace\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e14 Elvitegravir: A Novel Monoketo Acid HIV-1 Integrase Strand Transfer Inhibitor 197\u003cbr\u003e \u003ci\u003eHisashi Shinkai, Masanori Sato, and Yuji Matsuzaki\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003ePart II Hepatitis C Virus\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003eSection VI Protease Inhibitors\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e15 Discovery and Development of Telaprevir 209\u003cbr\u003e \u003ci\u003eAnne-Laure Grillot, Luc J. Farmer, B. Govinda Rao, William P. Taylor, Ilan S. Weisberg, Ira M. Jacobson, Robert B. Perni, and Ann D. Kwong\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e16 Discovery and Development of BILN 2061 and Follow-up BI 201335 225\u003cbr\u003e \u003ci\u003eMontse Llinàs-Brunet and Peter W. White\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e17 Intervention of Hepatitis C Replication Through NS3-4A, the Protease Inhibitor Boceprevir 239\u003cbr\u003e \u003ci\u003eSrikanth Venkatraman and F. George Njoroge\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e18 Discovery and Development of the HCV NS3\/4A Protease Inhibitor Danoprevir (ITMN-191\/RG7227)257\u003cbr\u003e \u003ci\u003eScott D. Seiwert, Karl Kossen, Lin Pan, Jyanwei Liu, and Brad O. Buckman\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e19 Discovery and Development of the HCV Protease Inhibitor TMC 435 273\u003cbr\u003e \u003ci\u003ePierre Raboisson, Gregory Fanning, Herman de Kock, Åsa Rosenquist, René Verloes, and Kenneth Simmen\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003eSection VII HCV Polymerase Nucleoside Inhibitors\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e20 Discovery and Clinical Evaluation of the Nucleoside Analog Balapiravir (R1626) for the Treatment ofHCV Infection 287\u003cbr\u003e \u003ci\u003eKlaus Klumpp and David B. Smith\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e21 Discovery and Development of PSI-6130\/RG 7128 305\u003cbr\u003e \u003ci\u003ePhillip A. Furman, Michael J. Otto, and Michael J. Sofia\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003eSection VIII Other HCV Inhibitors\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e22 Discovery of Cyclophilin Inhibitor NIM811 as a Novel Therapeutic Agent for HCV 317\u003cbr\u003e \u003ci\u003eKai Lin\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e23 HCV Viral Entry Inhibitors 329\u003cbr\u003e \u003ci\u003eFlossie Wong-Staal, Guohong Liu, and Jeffrey McKelvy\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003ePart III Respiratory Syncytial Virus Inhibitors\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e24 Discovery of the RSV Inhibitor TMC 353121 341\u003cbr\u003e \u003ci\u003eJean-François Bonfanti, Gabriela Ispas, Frans Van Velsen, Wieslawa Olszewska, Tom Gevers, and Dirk Roymans\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e25 Discovery and Development of Orally Active RSV Fusion Inhibitors 353\u003cbr\u003e \u003ci\u003eNicholas A. Meanwell, Christopher W. Cianci, and Mark R. Krystal\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e26 Discovery and Development of RSV 604 367\u003cbr\u003e \u003ci\u003eJoanna Chapman and G. Stuart Cockerill\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003ePart IV Influenza, Hepatitis B, and Cytomegalovirus Inhibitors\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e27 Discovery and Development of Influenza Virus Sialidase Inhibitor Relenza 385\u003cbr\u003e \u003ci\u003eRobin Thomson and Mark von Itzstein\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e28 Discovery and Development of Entecavir 401\u003cbr\u003e \u003ci\u003eRichard Wilber, Bruce Kreter, Marc Bifano, Stephanie Danetz, Lois Lehman-McKeeman, Daniel J. Tenney, Nicholas Meanwell, Robert Zahler, and Helena Brett-Smith\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e29 Benzimidazole Ribonucleosides: Novel Drug Candidates for the Prevention and Treatment ofCytomegalovirus Diseases 417\u003cbr\u003e \u003ci\u003eKaren K. Biron, Kristjan S. Gudmundsson, and John C. Drach\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eIndex 435\u003c\/p\u003e  \"I very much enjoyed this book and learned greatly from it ... The book is a valuable resource for researchers working in the discovery and early development of antiviral agents, and also for those simply interested in this area.\" (ChemMedChem, 1 January 2012)  \u003cp\u003e \u003c\/p\u003e \u003cb\u003eWieslaw M. Kazmierski\u003c\/b\u003e, PhD, has worked on novel HIV and HCV therapies in both small and large pharma settings in the last two decades, helping to advance molecules to clinical trials. Dr. Kazmierski has authored numerous peer reviewed publications and has been named a co-inventor on many patents. He has edited scientific books and had served on journal editorial boards.  \u003cp\u003eA complete, one-stop reference to real-world antiviral drug discovery and development\u003c\/p\u003e \u003cp\u003eThe field of antiviral drugs continues to evolve at a fast pace in response to new virus discoveries and development of viral resistance to existing therapies. This book provides case histories and arms both basic and industrial pharmaceutical researchers with practical tools to tackle the ongoing challenges of antiviral drug design, discovery, and development.\u003c\/p\u003e \u003cp\u003eWritten by leading authorities from academia and industry, Antiviral Drugs compiles information previously scattered across the literature into one complete, self-contained volume, unlike any other book on the subject. The authors draw on their own extensive research experience to present numerous case studies illustrating the full drug design process, from bench to clinic, with special emphasis on proven strategies for the development of drugs against all major viral infectious diseases, including HIV, HCV, RSV, influenza, HBV, and CMV.\u003c\/p\u003e \u003cp\u003eReaders will find everything they need to analyze, understand, and apply discovery and development principles, including:\u003c\/p\u003e \u003cul\u003e \u003cli\u003e \u003cp\u003eCoverage of newly approved antiviral drugs and compounds in clinical development\u003c\/p\u003e \u003c\/li\u003e \u003cli\u003e \u003cp\u003eEmphasis on novel experimental molecules used to combat viral infections\u003c\/p\u003e \u003c\/li\u003e \u003cli\u003e \u003cp\u003eViral inhibitory mechanistic information\u003c\/p\u003e \u003c\/li\u003e \u003cli\u003e \u003cp\u003eClear examples for how to bring drugs from laboratory discovery to clinical trials\u003c\/p\u003e \u003c\/li\u003e \u003cli\u003e \u003cp\u003eEffective examples and strategies of lead optimization yielding molecules of clinical value\u003c\/p\u003e \u003c\/li\u003e \u003cli\u003e \u003cp\u003ePractical solutions for issues such as pharmacokinetics, viral resistance, and more\u003c\/p\u003e \u003c\/li\u003e \u003cli\u003e \u003cp\u003eKey and specific references for readers wishing to explore the topics further\u003c\/p\u003e \u003c\/li\u003e \u003c\/ul\u003e","brand":"Wiley","offers":[{"title":"Default Title","offer_id":47988746551525,"sku":"NP9780470455630","price":191.95,"currency_code":"USD","in_stock":false}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1842\/7735\/files\/9780470455630.jpg?v=1761781429","url":"https:\/\/k12savings.com\/es\/products\/antiviral-drugs-isbn-9780470455630","provider":"K12savings","version":"1.0","type":"link"}